| 1 |
Review Pregabalin for fibromyalgia: some relief but no cure. free! 2009
Kim L, Lipton S, Deodhar A. · Division of Arthritis and Rheumatic Diseases (OP09), Oregon Health & Science University, Portland, OR 97239, USA. · Cleve Clin J Med. · Pubmed #19339642 links to free full text
Abstract: What is the role of pregabalin (Lyrica) in the treatment of fibromyalgia? In this article the authors explore the putative pathophysiology of fibromyalgia, pregabalin's mechanism of action and evidence of efficacy, and its emerging role in treating this challenging disease.
|
| 2 |
Review Myofascial pain syndromes and their evaluation. 2007
Bennett R. · Oregon Health & Science University, SNORD-219, Portland, OR 97239-2941, USA. · Best Pract Res Clin Rheumatol. · Pubmed #17602992 No free full text.
Abstract: Myofascial pain refers to a specific form of soft-tissue rheumatism that results from irritable foci (trigger points) within skeletal muscles and their ligamentous junctions. It must be distinguished from bursitis, tendonitis, hypermobility syndromes, fibromyalgia and fasciitis. On the other hand it often exists as part of a clinical complex that includes these other soft-tissue conditions, i.e., it is not a diagnosis of exclusion. The clinical science of trigger points can be traced to the pioneering work of Kellgren in the 1930s, with his mapping of myotomal referral patterns of pain resulting from the injection of hypertonic saline into muscle and ligaments. Most muscles have characteristic myotomal patterns of referred pain; this feature forms the basis of the clinical recognition of myofascial trigger points in the form of a tender locus within a taut band of muscle which restricts the full range of motion and refers pain centrifugally when stimulated. Although myofascial pain syndromes have been described in the medical literature for about the last 100 years, it is only recently that scientific studies have revealed objective abnormalities.
|
| 3 |
Review Growth hormone perturbations in fibromyalgia: a review. 2007
Jones KD, Deodhar P, Lorentzen A, Bennett RM, Deodhar AA. · Division of Arthritis & Rheumatic Diseases, School of Medicine, Oregon Health & Science University School of Nursing, 3455 SW U.S. Veterans Hospital Road, Portland, OR 97239, USA. · Semin Arthritis Rheum. · Pubmed #17224178 No free full text.
Abstract: OBJECTIVE: Fibromyalgia (FM) is a syndrome characterized by chronic widespread pain, fatigue, disrupted sleep, depression, and physical deconditioning. In this article, we review the literature on the normal activity of the hypothalamic-pituitary-growth hormone-insulin-like growth factor-1 (HP-GH-IGF-1) axis and its perturbations in FM subjects. METHODS: Studies included in this review were accessed through an English language search of Cochrane Collaboration Reviews. Keyword MeSH terms included "fibromyalgia," "growth hormone" (GH), or "insulin-like growth factor-1" (IGF-1). RESULTS: Twenty-six studies enrolling 2006 subjects were reviewed. Overall, low levels of IGF-1 were found in a subgroup of subjects. Growth hormone stimulation tests often revealed a suboptimal response, which did not always correlate with IGF-1 levels. No consistent defects in pituitary function were found. Of the 3 randomized placebo controlled studies, only 9 months of daily injectable recombinant GH reduced FM symptoms and normalized IGF-1. CONCLUSIONS: These studies suggest that pituitary function is normal in FM and that reported changes in the HP-GH-IGF-1 axis are most likely hypothalamic in origin. The therapeutic efficacy of supplemental GH therapy in FM requires further study before any solid recommendations can be made.
|
| 4 |
Review A comprehensive review of 46 exercise treatment studies in fibromyalgia (1988-2005). free! 2006
Jones KD, Adams D, Winters-Stone K, Burckhardt CS. · School of Nursing, Oregon Health & Science University, Portland, Oregon, USA. · Health Qual Life Outcomes. · Pubmed #16999856 links to free full text
Abstract: The purpose of this review was to: (1) locate all exercise treatment studies of fibromyalgia (FM) patients from 1988 through 2005, (2) present in tabular format the key details of each study and (3) to provide a summary and evaluation of each study for exercise and health outcomes researchers. Exercise intervention studies in FM were retrieved through Cochrane Collaboration Reviews and key word searches of the medical literature, conference proceedings and bibliographies. Studies were reviewed for inclusion using a standardized process. A table summarizing subject characteristics, exercise mode, timing, duration, frequency, intensity, attrition and outcome variables was developed. Results, conclusions and comments were made for each study. Forty-six exercise treatment studies were found with a total of 3035 subjects. The strongest evidence was in support of aerobic exercise a treatment prescription for fitness and symptom and improvement. In general, the greatest effect and lowest attrition occurred in exercise programs that were of lower intensity than those of higher intensity. Exercise is a crucial part of treatment for people with FM. Increased health and fitness, along with symptom reduction, can be expected with exercise that is of appropriate intensity, self-modified, and symptom-limited. Exercise and health outcomes researchers are encouraged to use the extant literature to develop effective health enhancing programs for people with FM and to target research to as yet understudied FM subpopulations, such as children, men, older adults, ethnic minorities and those with common comorbidities of osteoarthritis and obesity.
|
| 5 |
Review Physical therapy and other nonpharmacologic approaches to fibromyalgia management. 2006
Blehm R. · Portland VA Medical Center, 3710 SW US Vets Hospital Road, P3-PM&RS, Portland, OR 97207, USA. · Curr Pain Headache Rep. · Pubmed #16945248 No free full text.
Abstract: Fibromyalgia is a vague and changing syndrome that comprises many symptoms. Due to the confounding nature of fibromyalgia syndrome, there has been much debate about which interventions and therapies should be considered as viable treatment options. Opinions continue to shift in publication and research circles, with little documentation to show good, long-term outcomes. Several studies have shown promise, with initial improvement in symptoms, but in many cases, these improvements were not lasting or the patients were then unable to continue/replicate the program on their own. In this article, some of the more recently published findings regarding the efficacy of exercise are explored, specifically physical therapy and other nonpharmacologic interventions, for managing fibromyalgia syndrome.
|
| 6 |
Review Update on rheumatologic mimics of fibromyalgia. 2006
Hwang E, Barkhuizen A. · Oregon Health and Science University, 3181 SW Sam Jackson Park Road, OP09, Portland, OR 97239, USA. · Curr Pain Headache Rep. · Pubmed #16945247 No free full text.
Abstract: Fibromyalgia is a common disorder of diffuse musculoskeletal pain. Several rheumatic diseases can mimic fibromyalgia, and a clinician would not want to miss these diagnoses because of their potential long-term sequelae, such as progressive joint damage or life- or organ-threatening disease if they remain untreated. This paper discusses the typical clinical presentations of selected rheumatic diseases (systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, polymyalgia rheumatica, and osteoarthritis) then highlights the key features in history, laboratory testing, and radiographic imaging that aid the clinician in differentiating between fibromyalgia and these rheumatic diseases.
|
| 7 |
Review Cognitive behavioral therapy for fibromyalgia. 2006
Bennett R, Nelson D. · Oregon Health & Science University, Portland, OR 97239, USA. · Nat Clin Pract Rheumatol. · Pubmed #16932733 No free full text.
Abstract: Cognitive behavioral therapy (CBT) techniques offer short-term, goal-oriented psychotherapy. In this respect, it differs from classical psychoanalysis in emphasizing changes in thought patterns and behaviors rather than providing 'deep insight'. Importantly, the beneficial effects of CBT can be achieved in 10-20 sessions, compared with the many years required for classical psychoanalysis. Although CBT is often done on a one-to-one basis, it also lends itself to a group therapeutic setting. CBT was initially used in the treatment of mood disorders, but its use has subsequently been expanded to include various other medical conditions, including chronic pain states. Over the past 18 years, several chronic pain treatment programs have used CBT techniques in the management of fibromyalgia. In this review, the results from 13 programs using CBT, alone or in combination with other treatment modalities, are analyzed. In most studies, CBT provided worthwhile improvements in pain-related behavior, self-efficacy, coping strategies and overall physical function. Sustained improvements in pain were most evident when individualized CBT was used to treat patients with juvenile fibromyalgia. The current data indicate that CBT, as a single treatment modality, does not offer any distinct advantage over well-planned group programs of education or exercise, or both. Its role in the management of fibromyalgia patients needs further research.
|
| 8 |
Review Multidisciplinary approaches for management of fibromyalgia. 2006
Burckhardt CS. · Oregon Health & Science University, Portland, OR 97239, USA. · Curr Pharm Des. · Pubmed #16454725 No free full text.
Abstract: Multidisciplinary approaches to fibromyalgia syndrome (FMS) treatment are advocated for treating the complex symptoms and problems confronting many patients. Exercise and cognitive-behavioral strategies together with patient education commonly comprise the multidisciplinary approach to treatment in clinical trials. A review of the research literature suggests that they are effective for decreasing pain and FMS impact and increasing self-efficacy and physical functioning. Limitations of the current evidence base include a lack of studies that include medication treatment as part of the multidisciplinary approach as well as lack of attention to the diversity of patient psychosocial issues that may interfere with treatment effectiveness. The review recommends that further randomized clinical trials be carried out with subgroups of patients using standardized outcome measurements, adequate treatment length and sufficient length of follow-up to be able to observe and document changes in patient symptoms and behaviors over time.
|
| 9 |
Review Fibromyalgia: present to future. 2005
Bennett R. · Department of Medicine, Oregon Health & Science University, Portland, OR 97201, USA. · Curr Rheumatol Rep. · Pubmed #16174485 No free full text.
Abstract: There has been a dramatic increase in our understanding of fibromyalgia throughout the past 14 years since the publication of the 1990 American College of Rheumatology classification criteria. Before 1990, and for most of the 20th century, fibromyalgia was considered to be predominantly a muscle disorder; now the critical abnormality is described as "central sensitization." However, central sensitization has to have an initial genesis and nociceptive stimuli from painful foci in muscle are increasingly recognized as being relevant to the development of fibromyalgia. Clinicians also recognize an association between the initiation of fibromyalgia and chronic psychologic stressors and inflammatory disorders. It has been more difficult to understand how two such apparently diverse events could affect central pain physiology. However, some clues are emerging from the role of diverse stimuli in activating glial cells and the role of disordered cytokine networks. Some predictions about future developments in fibromyalgia are ventured based on the current state of knowledge.
|
| 10 |
Review Growth hormone in musculoskeletal pain states. 2005
Bennett R. · Department of Medicine (OP09), Oregon Health & Science University, Portland, OR 97201, USA. · Curr Pain Headache Rep. · Pubmed #16157062 No free full text.
Abstract: Growth hormone is essential for normal linear growth and the attainment of an adult mature height. It also plays an important role in cartilage growth and the attainment of normal bone mass. There is only one rheumatic disorder, namely acromegaly, in which abnormalities of growth hormone production play a major etiologic role. However, there is increasing appreciation that suboptimal growth hormone secretion, leading to a state of adult growth hormone deficiency, may occur in the setting of chronic inflammatory disease, chronic corticosteroid use, and fibromyalgia. Therefore, the evaluation and effective management of growth hormone oversecretion and undersecretion is relevant to practicing rheumatologists.
|
| 11 |
Review Review of the Chinese medical approach to the management of fibromyalgia. 2005
Zheng L, Faber K. · The Oregon College of Oriental Medicine, Portland, OR 97216-2859, USA. · Curr Pain Headache Rep. · Pubmed #16157057 No free full text.
Abstract: Traditional Chinese medicine (TCM) has a long history of efficacy in treating chronic illness. TCM views fibromyalgia and related conditions as disorders in the movement of energy (Qi) and body fluids (including blood) in the body and gets excellent treatment results using acupuncture, herbal medicine, massage, diet, and exercise to restore the proper flow of Qi and fluids. This article briefly introduces the TCM model of human physiology and TCM diagnostics and describes the TCM pathophysiology and treatment models for fibromyalgia.
|
| 12 |
Review Pharmacologic treatment of fibromyalgia. 2005
Baker K, Barkhuizen A. · Arthritis & Rheumatic Diseases, Oregon Health & Science University, OP-09, Portland, OR 97239, USA. · Curr Pain Headache Rep. · Pubmed #16157056 No free full text.
Abstract: Fibromyalgia is a syndrome of widespread pain, nonrestorative sleep, disturbed mood, and fatigue. Optimal treatment involves a multidisciplinary approach with a team of health care providers using pharmacologic and nonpharmacologic treatment. Because of the heterogeneity of the illness, management should be individualized for the patient. Pharmacologic treatment should address issues of pain control, sleep disturbance, fatigue, and any underlying coexisting mood disorder. Nonpharmacologic treatment should include patient education, a regular exercise and stretching program, and cognitive behavioral therapy. All of these are essential to improving functional capacity and quality of life. This review provides general guidelines in initiating a successful pharmacologic treatment program for patients with fibromyalgia.
|
| 13 |
Review Educating patients: self-management approaches. 2005
Burckhardt CS. · Oregon Health & Science University Portland, OR 97239, USA. · Disabil Rehabil. · Pubmed #16012063 No free full text.
Abstract: PURPOSE: To review and evaluate approaches to educating patients with fibromyalgia syndrome (FMS). METHODS: A narrative literature review was undertaken to summarize the published literature on patient education for FMS patients. RESULTS: A number of studies contain specific education strategies while others are combined with exercise or movement therapies or cognitive-behavioural therapy. CONCLUSIONS: Self-efficacy provides an effective theoretical model from which to understand how patients change as a result of education strategies that focus on self-management. Programmes that combine education with cognitive-behavioural techniques and exercise are most effective in enhancing self-efficacy and decreasing symptoms of FMS.
|
| 14 |
Review Medically unexplained symptoms and neuropsychological assessment. 2004
Binder LM, Campbell KA. · Oregon Health and Sciences University, Portland, OR, USA. · J Clin Exp Neuropsychol. · Pubmed #15512927 No free full text.
Abstract: Several illnesses expressed somatically that do not have clearly demonstrated pathophysiological origin and that are associated with neuropsychological complaints are reviewed. Among them are nonepileptic seizures, fibromyalgia, chronic fatigue syndrome, Persian Gulf War unexplained illnesses, toxic mold and sick building syndrome, and silicone breast implant disease. Some of these illnesses may be associated with objective cognitive abnormalities, but it is not likely that these abnormalities are caused by traditionally defined neurological disease. Instead, the cognitive abnormalities may be caused by a complex interaction between biological and psychological factors. Nonepileptic seizures serve as an excellent model of medically unexplained symptoms. Although nonepileptic seizures clearly are associated with objective cognitive abnormalities, they are not of neurological origin. There is evidence that severe stressors and PTSD are associated with immune system problems, neurochemical changes, and various diseases; these data blur the distinctions between psychological and organic etiologies. Diagnostic problems are intensified by the fact that many patients are poor historians. Patients are prone to omit history of severe stressors and psychiatric problems, and the inability to talk about stressors increases the likelihood of suffering from physiological forms of stress.
|
| 15 |
Review Motivational interviewing may encourage exercise in persons with fibromyalgia by enhancing self efficacy. free! 2004
Jones KD, Burckhardt CS, Bennett JA. · Oregon Health & Science University, Portland, Oregon, USA. · Arthritis Rheum. · Pubmed #15478154 links to free full text
This publication has no abstract.
|
| 16 |
Review Fibromyalgia: present to future. 2004
Bennett R. · Department of Medicine, Oregon Health & Science University, 3181 Sam Jackson Park Road, Portland, OR 97201, USA. · Curr Pain Headache Rep. · Pubmed #15361322 No free full text.
Abstract: There has been a dramatic increase in our understanding of fibromyalgia throughout the past 14 years since the publication of the 1990 American College of Rheumatology classification criteria. Before 1990, and for most of the 20th century, fibromyalgia was considered to be predominantly a muscle disorder; now the critical abnormality is described as "central sensitization." However, central sensitization has to have an initial genesis and nociceptive stimuli from painful foci in muscle are increasingly recognized as being relevant to the development of fibromyalgia. Clinicians also recognize an association between the initiation of fibromyalgia and chronic psychologic stressors and inflammatory disorders. It has been more difficult to understand how two such apparently diverse events could affect central pain physiology. However, some clues are emerging from the role of diverse stimuli in activating glial cells and the role of disordered cytokine networks. Some predictions about future developments in fibromyalgia are ventured based on the current state of knowledge.
|
| 17 |
Review Growth hormone in musculoskeletal pain states. 2004
Bennett R. · Oregon Health & Science University, Department of Medicine (OP09), 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA. · Curr Rheumatol Rep. · Pubmed #15251074 No free full text.
Abstract: Growth hormone is essential for normal linear growth and the attainment of an adult mature height. It also plays an important role in cartilage growth and the attainment of normal bone mass. There is only one rheumatic disorder, namely acromegaly, in which abnormalities of growth hormone production play a major etiologic role. However, there is increasing appreciation that suboptimal growth hormone secretion, leading to a state of adult growth hormone deficiency, may occur in the setting of chronic inflammatory disease, chronic corticosteroid use, and fibromyalgia. Therefore, the evaluation and effective management of growth hormone oversecretion and undersecretion is relevant to practicing rheumatologists.
|
| 18 |
Review Fibromyalgia, hepatitis C infection, and the cytokine connection. 2003
Thompson ME, Barkhuizen A. · Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, 3181 Sam Jackson Park Road OP-09, Portland, OR 97239, USA. · Curr Pain Headache Rep. · Pubmed #12946286 No free full text.
Abstract: Fibromyalgia and chronic hepatitis C infection share many clinical features including prominent somatic complaints such as musculoskeletal pain and fatigue. There is a growing body of evidence supporting a link between cytokines and somatic complaints. This review discusses alterations of cytokines in fibromyalgia, including increased serum levels of interleukin (IL)-2, IL-2 receptor, IL-8, IL-1 receptor antagonist; increased IL-1 and IL-6 produced by stimulated peripheral blood mononuclear cell in patients with FM for longer than 2 years; increased gp130, which is a neutrophil cytokine transducing protein; increased soluble IL-6 receptor and soluble IL-1 receptor antagonist only in patients with fibromyalgia who are depressed; and IL-1 beta, IL-6, and TNF-a by reverse transcriptase-polymerase chain reaction in skin biopsies of some patients with fibromyalgia. In addition, this review describes the mechanism by which alterations in cytokines in fibromyalgia and chronic hepatitis C infection can produce hyperalgesia and other neurally mediated symptoms through the presence of cytokine receptors on glial cells and opiate receptors on lymphocytes and the influence of cytokines on the hypothalamus-pituitary-adrenal axis such as IL-1, IL-6, and TNF-a activating and IL-2 and IFN-a down-regulating the HPA axis, respectively. The association between chronic hepatitis C infection and fibromyalgia is discussed, including a description of key cytokine changes in chronic hepatitis C infection. Future studies are encouraged to further characterize these immunologic alterations with potential pathophysiologic and therapeutic implications.
|
| 19 |
Review Adult growth hormone deficiency in patients with fibromyalgia. 2002
Bennett RM. · Oregon Health & Science University, Department of Medicine (OP09), Portland, OR 97201, USA. · Curr Rheumatol Rep. · Pubmed #12126582 No free full text.
Abstract: Adult growth hormone (GH) deficiency is a well-described clinical syndrome with many features reminiscent of fibromyalgia. There is evidence that GH deficiency as defined in terms of a low insulin-like growth factor-1 (IGF-1) level occurs in approximately 30% of patients with fibromyalgia and is probably the cause of some morbidity. It seems most likely that impaired GH secretion in fibromyalgia is related to a physiologic dysregulation of the hypothalamic-pituitary-adrenal axis (HPA) with a resulting increase in hypothalamic somatostatin tone. It is postulated that impaired GH secretion is secondary to chronic physical and psychological stressors. It appears that impaired GH secretion is more common than clinically significant GH deficiency with low IGF-1 levels. The severe GH deficiency that occurs in a subset of patients with fibromyalgia is of clinical relevance because it is a treatable disorder with demonstrated benefits to patients.
|
| 20 |
Review Individualizing the exercise prescription for persons with fibromyalgia. 2002
Jones KD, Clark SR. · School of Nursing, Oregon Health and Science University, SN-5S, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA. · Rheum Dis Clin North Am. · Pubmed #12122928 No free full text.
Abstract: "Exercise is good for you; you must exercise, and just do it" are common admonitions to fibromyalgia (FM) patients by health professionals. "I can't exercise; I hurt too much to exercise; and, I don't have enough energy to exercise" are equally common responses from patients with FM. Such exchanges can lead to frustration for both patient and provider. The factor that neither participant in the dialogue is addressing is that exercise carries both risks and benefits for persons with FM. Although for decades exercise has been acknowledged to be a key component of the treatment of FM, the majority of FM patients remain aerobically unfit, with poor muscle strength and limited flexibility. Unfit muscle is theoretically more prone to muscle microtrauma, which causes localized pain and may trigger widespread pain through disordered central processing. The purpose of this article is to provide practicing health care providers with guidelines for prescribing exercise to FM patients that take into account the risk/benefit ratio. A sample exercise prescription is included.
|
| 21 |
Review Nonpharmacologic management strategies in fibromyalgia. 2002
Burckhardt CS. · School of Nursing, SN-5N, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA. · Rheum Dis Clin North Am. · Pubmed #12122918 No free full text.
Abstract: Clinicians using the results of the extant research base can take an optimistic view of the role of nonpharmacologic treatment strategies for fibromyalgia. There were no negative outcomes in any of the reviewed studies, although in a few studies the experimental treatment did not prove to be more effective than the attention control. Rather than viewing this negatively, one could look more closely at the attention control groups and attempt to better understand what they contained that worked as an active treatment. A number of trials include a follow-up component and all but one of them find maintenance of at least one outcome change. Maintenance of changes is more likely to occur when the patient continues to participate in the experimental activity long-term. Patients especially need strategies that help them continue in exercise regimens. Unlike cognitive skills strategies that once learned are likely to become part of a person's coping repertoire, both exercise and behavioral strategies, like progressive muscle relaxation, need to be performed on a consistent basis in order to have their effect. The goals of increased self-efficacy, symptom reduction, increased functional status and quality of life along with decreased inappropriate use of health care resources are realistic when patients persevere in their use of strategy combinations and receive support from their providers.
|
| 22 |
Review Rational and targeted pharmacologic treatment of fibromyalgia. 2002
Barkhuizen A. · Department of Medicine, Oregon Health and Science University, Portland VA Medical Center, Portland, OR, USA. · Rheum Dis Clin North Am. · Pubmed #12122917 No free full text.
Abstract: Despite disappointing results when subjected to randomized clinical trials, pharmacologic agents remain an important component of FM management. Addressing the main symptoms of pain, disturbed sleep, mood disturbances, fatigue, and associated conditions is essential to improve patient functioning and enhanced quality of life. However, much work remains to design clinical trials which address the complexity of FM, while satisfying evidence based medicine paradigms.
|
| 23 |
Review The rational management of fibromyalgia patients. 2002
Bennett RM. · Department of Medicine (OP09), Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA. · Rheum Dis Clin North Am. · Pubmed #12122913 No free full text.
Abstract: The exponential increase in pain research over the last 10 years has established fibromyalgia (FM) as a common chronic pain syndrome with similar neurophysiologic aberrations to other chronic pain states. As such, the pathogenesis is considered to involve an interaction of augmented sensory processing (central sensitization) and peripheral pain generators. The notion, that FM symptomatology results from an amplification of incoming sensory impulses, has revolutionized the contemporary understanding of this enigmatic problem and provided a more rational approach to treatment. To date, the management of FM has been mainly palliative, with the aims of reducing pain, improving sleep, maintaining function, treating psychologic distress and diminishing the impact of associated syndromes. The rapidly evolving neurophysiologic, psychophysiologic and molecular biologic basis for chronic pain states has already opened up new avenues for management which should be applicable to this difficult group of patients. Indeed, it is now possible to think about a "rational" approach to managing FM patients that was unthinkable just a few years ago.
|
| 24 |
Review Rheumatic mimics and selected triggers of fibromyalgia. 2002
Daoud KF, Barkhuizen A. · Oregon Health and Science University, Division of Rheumatology, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA. · Curr Pain Headache Rep. · Pubmed #12095463 No free full text.
Abstract: Fibromyalgia is a chronic pain syndrome of unknown etiology characterized by diffuse pain and tender points, which have been present for more than 3 months. Many patients with systemic illnesses can have diffuse pain similar to that found in fibromyalgia, including rheumatic diseases such as polymyalgia rheumatica, rheumatoid arthritis, idiopathic inflammatory myopathy, systemic lupus erythematosus, and joint hypermobility. Osteomalacia and thyroid disease are also in the differential diagnosis of diffuse pain and are imminently treatable. In addition, there has been interest throughout the past 10 years in infectious diseases including hepatitis C, Lyme disease, coxsackie B, HIV, and parvovirus infection, which may cause or trigger fibromyalgia. This paper provides a framework to use when identifying these diseases as part of the evaluation of a patient with chronic widespread musculoskeletal pain.
|
| 25 |
Review Pharmacologic treatment of fibromyalgia. 2001
Barkhuizen A. · Department of Medicine (L329A), Oregon Health Sciences University and Portland VA Medical Center, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA. · Curr Pain Headache Rep. · Pubmed #11403739 No free full text.
Abstract: Fibromyalgia is a chronic syndrome characterized by widespread pain, unrefreshed sleep, disturbed mood, and fatigue. Until such time as we have a clearer understanding of the trigger and/or pathophysiologic mechanisms producing these symptoms, pharmacologic treatment should be aimed at individual symptoms. Such treatment should ideally be offered as part of a multidisciplinary treatment program using both pharmacologic and nonpharmacologic treatment modalities. Critical components of any successful fibromyalgia treatment program include addressing physical fitness, work and other functional activities, and mental health, in addition to symptom-specific therapies. The main symptoms that should be addressed include pain, sleep disturbances including restless leg syndrome, mood disturbances, and fatigue. Pharmacologic therapy should also be considered for syndromes commonly associated with fibromyalgia including irritable bowel syndrome, interstitial cystitis, migraine headaches, temporomandibular joint dysfunction, dysequilibrium including neurally mediated hypotension, sicca syndrome, and growth hormone deficiency. This article provides general guidelines in initiating a successful pharmacologic treatment program for fibromyalgia.
|
Next |
|
|